BioLife will acquire Sexton Biotechnologies, which develops and markets biomanufacturing tools for cell and gene therapy. Sexton's tools portfolio includes proprietary vials for cell therapy products, fetal serum replacement used in manufacturing and automated cell processing equipment. The deal will be valued at $24 million and is scheduled to close after Sept. 1, 2021.